A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumor|Breast Cancer|Non Small Cell Lung Cancer|Ovary Cancer|Pancreatic Neoplasms
Interventions: DRUG: MB1707
Sponsor: Mainline Biosciences, Inc.